复星医药:斯鲁利单抗注射液获欧盟孤儿药资格认定

互动易
11 Feb

有投资者向复星医药提问, 请问下复星管理层,复宏汉霖微信公众号中标题为“界面新闻专访复宏汉霖李锦:带着国产创新药敲开欧美药监的门”中提及的H药欧盟申请孤儿药资格申诉是否成功?H药欧盟获批时间是否受到影响推迟?H药美国三期桥接试验进展情况及预计申请上市时间?公司回答表示,投资者您好!斯鲁利单抗注射液用于治疗小细胞肺癌已于2022年12月获欧盟委员会授予孤儿药资格认定,且斯鲁利单抗注射液联合卡铂和依托...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10